CompletedPHASE2, PHASE3NCT00354120
Thymoglobuline Versus Alemtuzumab in Patients Undergoing Allogeneic Transplant
Studying Acute panmyelosis with myelofibrosis
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Gruppo Italiano Trapianto di Midollo Osseo
- Principal Investigator
- Alessandro Rambaldi, MDDivisione di Ematologia - Ospedali Riuniti di Bergamo
- Intervention
- Alentuzumab(drug)
- Enrollment
- 121 enrolled
- Eligibility
- 18-65 years · All sexes
- Timeline
- 2005 – 2011
Study locations (22)
- Ematologia e Centro Trapianti Midollo Osseo - Ospedale IRCCS Casa Sollievo della Sofferenza, San Giovanni Rotondo, Foggia, Italy
- Divisione Ematologia - Ospedale "SS. Antonio, Biagio e Cesare Arrigo", Alessandria, Italy
- Clinica di Ematologia - Ospedali Riuniti di Ancona, Ancona, Italy
- Divisione di Ematologia - Ospedali Riuniti Bergamo, Bergamo, Italy
- S.C. Ematologia - Azienda Ospedaliera S. Croce e Carle, Cuneo, Italy
- Cattedra di Ematologia - Azienda Ospedaliera di Careggi, Florence, Italy
- Trapianti Midollo Osseo - Div. di Ematologia 2 - Ospedale S. Martino, Genova, Italy
- Divisione di Ematologia - Istituto Nazionale dei Tumori, Milan, Italy
- U.O. Ematologia I - Centro Trapianti di Midollo - Ospedale Maggiore - Policlinico Mangiagalli e Regina Elena, Milan, Italy
- Divisione Ematologia - Azienda Ospedaliera Universitaria - Policlinico -, Modena, Italy
- Cattedra di Medicina Interna ed Ematologia - Ospedale S. Gerardo de' i Tintori - Università degli Studi di Milano, Monza, Italy
- Divisione Ematologia con trapianto - Ospedale "V. Cervello", Palermo, Italy
- Dipartimento di Ematologia - IRCCS Policlinico S. Matteo - Università di Pavia, Pavia, Italy
- Dip. di Ematologia - Unità di Terapia Intensiva Ematologica per il Trapianto Emopoietico - Ospedale Civile di Pescara, Pescara, Italy
- Ematologia - Ospedale S. Chiara, Pisa, Italy
- +7 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT00354120 on ClinicalTrials.govOther trials for Acute panmyelosis with myelofibrosis
Additional recruiting or active studies for the same condition.
- RECRUITINGEARLY PHASE1NCT06398457Darzalex Faspro (Daratumumab and Hyaluronidase-fihj) Before Standard Desensitization and Allogeneic Peripheral Blood Stem Cell Transplantation in Adult Patients at High-risk for Primary Graft Failure Secondary to Donor Specific AntibodiesSidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- RECRUITINGNANCT05875805A Telehealth Advance Care Planning InterventionUniversity of Rochester
- ACTIVE NOT RECRUITINGPHASE1NCT05455294Combination Navitoclax, Venetoclax and Decitabine for Advanced Myeloid NeoplasmsJacqueline Garcia, MD
- RECRUITINGPHASE1NCT04771572Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL.Newave Pharmaceutical Inc
- ACTIVE NOT RECRUITINGPHASE2NCT04060277Triplex Vaccine in Preventing CMV Infection in Patients Undergoing Hematopoietic Stem Cell TransplantationCity of Hope Medical Center
- ACTIVE NOT RECRUITINGPHASE3NCT03480360Haploidentical Allogeneic Peripheral Blood Transplantation: Examining Checkpoint Immune Regulators' ExpressionDartmouth-Hitchcock Medical Center